is the recipient of a Miguel Servet contract by the Instituto de Salud Carlos III (grant number CPII18/00033)
is the recipient of a Miguel Servet contract by the Instituto de Salud Carlos III (grant number CPII18/00033). Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody units (BAU), a Glimepiride correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL equals 0.142 AU, as previously established by Abbott with the WHO international standard NIBSC 20136. Following the manufacturers recommendations, samples were regarded as reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protecting effect (PROT-80) against symptomatic SARS-CoV-2 illness was assumed when anti-S-RBD titers were 506 BAU/ml or higher. Charlson Comorbidity Index (CCI) score was classified as slight = 12, moderate = 34, and severe 5. Side effects were evaluated until day time 7 by individuals self-reported questionnaire. == Results == One hundred seven participants were enrolled [n= 84 homologous (SpV/SpV), nn 23 heterologous Glimepiride (SpV/Mod)]. Median (IQR) age was 64 (5075) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV Glimepiride and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 illness (p= 0.589). In the overall populace, 103 individuals reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (2885680) BAU/mL] than in the homologous plan [447 (1001551) BAU/mL],p= 0.022. Inside a linear model modified for age, gender, days from 1st vaccination to boost dose and days from your boost dose to the anti-S-RBD IgG dedication, previous SARS-COV-2 illness (B: 2062.2; CI95: 1231.82892.6;p< 0.001), and SpV/Mod vaccination plan (B: 1294.6; CI95: 435.582147.6;p= 0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous plan, although they were well tolerated by all individuals. == Conclusions == The present study provides evidence the homologous SpV/SpV and heterologous SpV/Mod techniques showed good effectiveness and security in individuals on chronic dialysis. These results could be useful for developing future vaccination strategies, especially aimed at this risk group. == Graphical abstract == Keywords:Dialysis, SARS-CoV-2, Vaccine, Heterologous plan, Gam-COVID-Vac, mRNA-1273 == Intro == Individuals on chronic dialysis are at improved risk for severe coronavirus infectious disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general populace, with reported mortality rates of up to 28.3% [1,2]. This situation is mainly related to a substantially higher mean patient age (approximately 65 years old) and the frequent presence of comorbid conditions such as obesity, diabetes, high blood pressure, socioeconomic deprivation, and frailty that are linked to a more severe COVID-19 course. Luckily, effective vaccination techniques against SARS-CoV-2 inducing reduction of both illness and the risk of severe COVID-19 have been rapidly developed [36]. Moreover, when facing 1st dose severe adverse effects or dose supply shortages, launched heterologous vaccination techniques have shown encouraging results [711]. However, clinical trials do not provide information about vaccine effectiveness in dialysis populations, and possible variations in immunogenicity among SARS-CoV-2 vaccination techniques are poorly recognized because of the novelty. Particularly, the homologous Gam-COVID-VAC (Sputnik V) and the heterologous vaccination plan including Sputnik V like a perfect dose and mRNA-1273 (Moderna) like a booster dose have been barely analyzed since Sputnik V is not approved in all countries, its implementation suffers geographic limitations, and its authorization from the Western Medicines Agency (EMA) and the World Health Business (WHO) is still awaited. Nonetheless, the National Administration of Medicines, Food, and Medical Technology of Argentina (ANMAT) authorized Sputnik V emergency use in late December 2020. Sputnik V authorization was followed by approval of the ChAdOx1 nCoV-19 vaccine (AZD1222), Sinopharm COVID19 (BBIBPCorV) vaccine, mRAN-1273 COVID-19 (Moderna), and BNT162b2 (Pfizer). However, due to the second dose shortage of Sputnik V, mRNA-1273 (Moderna) was regularly given as the booster dose. With this scenario, the present study targeted to assess the humoral response to homologous Sputnik V and heterologous Sputnik V/Moderna vaccination in dialysis individuals. == Materials and Methods Glimepiride == == Study Design and Populace == From March to October 2021, subjects who underwent hemodialysis in the Centro de Educacin Mdica e Investigaciones Clnicas Norberto Quirno (CEMIC), Buenos Aires, Argentina, were included in this prospective cohort study. Inclusion criteria were (i) having received Sputnik V perfect immunization, (ii) having received a TM4SF18 boost dose of either Sputnik V (SpV/SpV) or Moderna (SpV/Mod) vaccines within 18.